A Clinical Study on the Effect of Telmisartan with Alpha Lipoic Acid on Microalbuminuria in Type 2 Diabetes and Hypertensive Patients

摘要

Microalbuminuria, the clinical indicator of structural and physiological insult to kidneys, is not an uncommon presentation in chronic hypertensive patients. This six months Prospective Cohort study was conducted in the Department of General Medicine, Vivekanandha Medical Care Hospital. Totally, 272 patients with type 2 diabetes mellitus and hypertension were screened for microalbuminuria, out of which 66 patients were recruited for the study groups. Group I (Telmisartan 40 mg) included 31 patients and Group II (Telmisartan 40mg + Alpha Lipoic Acid 600mg) included 35 patients. The prevalence of microalbuminuria in patients with Type 2 Diabetes Mellitus and hypertension was 24.3%. Highest occurrence of microalbuminuria was found in the age group of 61-70 years (31.8%) and the prevalence was found to be higher in males (69.7%) when compared to females (30.3%). In patients with duration of disease more than 20 years, the prevalence of microalbuminuria was 33.33%. Compared to baseline, the urinary albumin excretion significantly decreased in Telmisartan + Alpha Lipoic Acid group (12.86 ± 0.07) than in Telmisartan group (6.19 ± 0.32). Alpha Lipoic Acid may reduce urinary albumin levels when given as an adjunct therapy with Telmisartan in microalbuminuria patients with type 2 diabetes mellitus and hypertension.